Calidi Biotherapeutics, INC 8-K filings

Calidi Biotherapeutics amended a $1.5 million convertible note to allow for repayment through participation in a future public offering.

Calidi Biotherapeutics has amended the terms of two convertible promissory notes, adjusting the conversion price and mandatory conversion conditions.

Calidi Biotherapeutics announced its fourth quarter and full-year 2023 financial results, highlighting progress in its clinical programs and the development of new immunotherapy platforms.

Calidi Biotherapeutics has amended a $1.5 million convertible note and settled disputes related to prior funding agreements by issuing new convertible notes.

Calidi Biotherapeutics has amended its bylaws to reduce the quorum requirement for stockholder meetings from a majority to one-third of voting power.

Calidi Biotherapeutics presented its systemic enveloped oncolytic virotherapy platform at the Biocom Global Life Science Partnering & Investor Conference on February 28, 2024.

Calidi Biotherapeutics has reached a settlement agreement regarding a dispute over stock options, issuing restricted shares and warrants to the involved physicians.

Calidi Biotherapeutics released preliminary financial estimates for the quarter and year ended December 31, 2023, including cash, cash used in operations, and indebtedness.

Calidi Biotherapeutics has entered into a convertible promissory note agreement with Ingodwe Trust, issuing warrants and a convertible note for a $1 million loan.